Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03370614 · ClinicalTrials.gov registry record

Pilot Study of the Physiological Effects of an Integrative Medicine Approach in Irritable Bowel Syndrome

A clinical trial of Irritable Bowel Syndrome, sponsored by Thomas Jefferson University.

Active
Registry status
50
Enrollment target
2
Study locations

NCT03370614: Active study of Irritable Bowel Syndrome, sponsored by Thomas Jefferson University.

NCT03370614 is a study of Irritable Bowel Syndrome that is active but no longer recruiting, run by Thomas Jefferson University. The registered enrollment target is 50 participants, below the 143-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target (65% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03370614, a study of Irritable Bowel Syndrome, is active but no longer recruiting, sponsored by Thomas Jefferson University.

ACTIVE NOT RECRUITING
Registry status
50 participants
Enrollment target
2
Study locations

Study Summary

Although underutilized, what is emerging as one of the best ways of evaluating inflammation in the body, particularly in difficult to observe regions, is through the use of Fluorodeoxyglucose (FDG) positron emission tomography (PET). FDG is taken up in the body much like glucose and is particularly taken up in areas of inflammation where there is increased metabolism. Therefore, this technology can be used to assess inflammation, and measure the reduction in inflammation as the result of integrative interventions that target dietary modifications designed to reduce inflammation. With this proposed study, we plan to use FDG PET-MRI technology to develop a more specific and sensitive approach for evaluating areas of inflammation associated with IBS and measuring improvements in that inflammation in response to effective integrative interventions.

Primary Outcome

To use PET-MRI to define abnormal brain and body activity and evaluate changes in inflammation for IBS patients.

Conditions Studied

Interventions

  • OTHER Healthy Control Group
  • OTHER IBS Group

Study Locations (2)

Pennsylvania

  • Thomas Jefferson University, Marcus Institute of Integrative Health Centers - Philadelphia
  • Thomas Jefferson University, Marcus Institute of Integrative Health Centers - Villanova

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2017-05-04
Est. Completion 2025-06-30
Thomas Jefferson University

292 total trials

What the registry record for NCT03370614 still lists

NCT03370614 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 143-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target (65% lower).

The record links to 1 condition, with Irritable Bowel Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Healthy Control Group is the first listed.

NCT03370614 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03370614 about?

NCT03370614 is a clinical study titled "Pilot Study of the Physiological Effects of an Integrative Medicine Approach in Irritable Bowel Syndrome". Although underutilized, what is emerging as one of the best ways of evaluating inflammation in the body, particularly in difficult to observe regions, is through the use of Fluorodeoxyglucose (FDG) positron emission tomography (PET). FDG is taken up in the body much like glucose and is particularly ...

What is the current status of trial NCT03370614?

This trial is currently active not recruiting. The enrollment target is 50 participants. The study started on 2017-05-04. Estimated completion is 2025-06-30.

What conditions does trial NCT03370614 study?

This clinical trial studies the following conditions: Irritable Bowel Syndrome.

What interventions are being tested in trial NCT03370614?

The interventions under investigation include: Healthy Control Group (OTHER), IBS Group (OTHER).

Who is sponsoring clinical trial NCT03370614?

This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03370614 being conducted?

This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Irritable Bowel Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03370614's enrollment target sits among peer trials

50 33rd of 47 higher than 14 of 47 other Irritable Bowel Syndrome trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Irritable Bowel Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03370614, the US trial registry maintained by the National Library of Medicine. NCT03370614 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.